Results 21 to 30 of about 9,882,917 (355)

Why musical memory can be preserved in advanced Alzheimer's disease [PDF]

, 2015
Musical memory is relatively preserved in Alzheimer's disease and other dementias. In a 7 Tesla functional MRI study employing multi-voxel pattern analysis, Jacobsen et al.
Chételat, Gael, Fritz, ThomasLW1780200091355331448AC4-F0EE-11E1-A9DE-61C894A0A6B4, Jacobsen, Jörn-Henrik, Kullmann, Dimitrieditor, Stelzer, Johannes   +4 more
core   +2 more sources

Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer's disease. [PDF]

, 2017
The abundance of mRNA is mainly determined by the rates of RNA transcription and decay. Here, we present a method for unbiased estimation of differential mRNA decay rate from RNA-sequencing data by modeling the kinetics of mRNA metabolism.
Alkallas, Rached, Fish, Lisa, Goodarzi, Hani, Najafabadi, Hamed S   +3 more
core   +3 more sources

Early affective changes and increased connectivity in preclinical Alzheimer's disease. [PDF]

, 2018
IntroductionAffective changes precede cognitive decline in mild Alzheimer's disease and may relate to increased connectivity in a "salience network" attuned to emotionally significant stimuli.
Bilgel, Murat, Brown, Jesse A, Fredericks, Carolyn A, Hua, Alice Y, Resnick, Susan M, Seeley, William W, Sturm, Virginia E, Wong, Dean F   +7 more
core   +1 more source

2021 Alzheimer's disease facts and figures

Alzheimer's & Dementia, 2021
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the challenges
Anonymous
semanticscholar   +1 more source

Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. [PDF]

, 2019
We identified a PSEN1 (presenilin 1) mutation carrier from the world's largest autosomal dominant Alzheimer's disease kindred, who did not develop mild cognitive impairment until her seventies, three decades after the expected age of clinical onset.
A Butler, A Lalazar, A Llado, Aaron P. Schultz, Ana Baena, Arabiye Artola, AS Fleisher, Claudia Marino, D Smedley, Daniel J. Norton, David Aguillon, David Leyton-Cifuentes, DC Aguirre-Acevedo, Dhanesh Amarnani, DM Walsh, DT Chien, E Hudry, EC Mormino, Edmarie Guzmán-Vélez, EH Corder, Enmanuelle Pardilla-Delgado, Eric M. Reiman, Francisco Lopera, Gyungah R. Jun, H Braak, H Braak, Henrik Zetterberg, J Logan, JA Becker, Ji Luo, JI Velez, Jianling Ji, JN Rauch, John B. Miller, Joseph F. Arboleda-Velasquez, Juliana Acosta-Uribe, Justin S. Sanchez, KA Johnson, Kahira L. Saez-Torres, Kaj Blennow, Keith A. Johnson, Kenneth S. Kosik, Kewei Chen, L Wang, L Zhong, Leo A. Kim, Lishuang Shen, M Futamura, M Gisslén, MA Lalli, Marcus Naymik, Margarita Giraldo, Matthew J. Huentelman, Matthew Lalli, Michael O’Hare, Moiz Bootwalla, MR Wardell, N Acosta-Baena, Natalia Chmielewska, O Preische, Pierre N. Tariot, Pradeep Thiyyagura, Rebecca A. Reiman, Reisa A. Sperling, RW Mahley, S Fisher, S Thordardottir, Santiago Delgado-Tirado, Silvia Rios-Romenets, T Hashimoto, T Hashimoto, T Hedden, TM Shoup, WD Knight, Xiaowu Gai, Y Yamauchi, Yakeel T. Quiroz, Yi Su, Yinghua Chen, YT Quiroz   +79 more
core   +3 more sources

Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2020
Introduction Federally funded Alzheimer's Disease Centers in the United States have been using a standardized neuropsychological test battery as part of the National Alzheimer's Coordinating Center Uniform Data Set (UDS) since 2005. Version 3 (V3) of the
Hiroko H. Dodge, Felicia C. Goldstein, Nicole I Wakim, Tamar Gefen, Merilee Teylan, Kwun C.G. Chan, Walter A. Kukull, Lisa L. Barnes, Bruno Giordani, Timothy M. Hughes, Joel H. Kramer, David A. Loewenstein, Daniel C. Marson, Dan M. Mungas, Nora Mattek, Bonnie C. Sachs, David P. Salmon, Monica Willis‐Parker, Kathleen A. Welsh‐Bohmer, Katherine V. Wild, John C. Morris, Sandra Weintraub, National Alzheimer's Coordinating Center (NACC)   +22 more
doaj   +1 more source

Deep learning improves utility of tau PET in the study of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
Introduction Positron emission tomography (PET) imaging targeting neurofibrillary tau tangles is increasingly used in the study of Alzheimer's disease (AD), but its utility may be limited by conventional quantitative or qualitative evaluation techniques ...
James Zou, David Park, Aubrey Johnson, Xinyang Feng, Michelle Pardo, Jeanelle France, Zeljko Tomljanovic, Adam M. Brickman, Devangere P. Devanand, José A. Luchsinger, William C. Kreisl, Frank A. Provenzano, for the Alzheimer's Disease Neuroimaging Initiative   +12 more
doaj   +1 more source

EEG UPPER/LOW ALPHA FREQUENCY POWER RATIO RELATES TO TEMPORO-PARIETAL BRAIN ATROPHY AND MEMORY PERFORMANCES IN MILD COGNITIVE IMPAIRMENT

Frontiers in Aging Neuroscience, 2013
Objective: temporo-parietal cortex thinning is associated to mild cognitive impairment (MCI) due to Alzheimer disease (AD). The increase of EEG upper/low alpha power ratio has been associated with AD-converter MCI subjects.
Davide Vito Moretti, donata epaternicò, Giuliano eBinetti, Orazio eZanetti, giovanni b Frisoni   +4 more
doaj   +1 more source

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer\u27s disease [PDF]

, 2019
Interest in understanding the roles of white matter (WM) inflammation and damage in the pathophysiology of Alzheimer disease (AD) has been growing significantly in recent years.
Ances, Beau M, Benzinger, Tammie L.S., Blazey, Tyler, Cairns, Nigel J, Chen, Charlie, Cruchaga, Carlos, Fagan, Anne M, Gordon, Brian A, Liu, Jingxia, Morris, John C, Shimony, Joshua S, Su, Yi, Sutphen, Courtney L, Wang, Qing, Wang, Yong   +14 more
core   +2 more sources

The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease [PDF]

, 2015
Alzheimer's disease (AD) is the most common form of dementia in the elderly and its prevalence is set to increase rapidly in coming decades. However, there are as yet no available drugs that can halt or even stabilize disease progression. One of the main
Baillie, George S., Cameron, Ryan T., Hillert, Ellin-Kristina, MacLeod, Ruth   +3 more
core   +1 more source